{"title": "Infection & Chemotherapy \uba54\ub974\uc2a4 \uc758\ub8cc\uae30\uad00 \uac10\uc5fc\uad00\ub9ac\uc9c0\uce68", "body": "2.\n\n(structure), (system), (processes) (BII).\n\n3.\n\n, (AIII). 4 . , (AIII).\n\n, (AII). 6 . , , , (AII).\n\n, ,\n\n. [3] .\n\n, ' ' '\n\n' [4] . , ' ' ' '\n\n(AIII) [5] [6] [7] .\n\n' , (standard, contact & droplet precaution)'\n\n(AIII). ,\n\n(airborne precaution)' (AIII) [8] [9] [10] . [11] .\n\n2) \uba54\ub974\uc2a4 \uac10\uc5fc\ub300\ucc45\uc704\uc6d0\ud68c \uad6c\uc131 (Table 2) . , , ,\n\n(AII) [11, 12] . 24 .\n\n, .\n\n. , (structure), (system), (processes) [13] .\n\n, (personal protective equipment, PPE) [11] .\n\n. , (AIII).\n\n, [14] , (AIII) [15] . , [16, 17] . , .\n\n.\n\n(CII) [18, 19] . [20] .\n\n, (AII) [21] .\n\n(AII) [5, 22, 23] . 1 .\n\n2 m (CIII) [15] . [17] . , [7] . , [24] .\n\n(AII) [25] .\n\n, (BII) [16] .\n\n. , , (BIII).\n\n. . [11] .\n\n(AII) [11] .\n\n. ,\n\n2 m , (BII) [5] .\n\n(BII) [5] .\n\n, (BII) [5] .\n\n(CIII) [26, 27] . (BIII).\n\n, .\n\n(AIII).\n\n( Table 3 ) (BIII) [28] .\n\n, , 12 30 ( Ta-ble 3 ) (AIII) [28] .\n\n. , . ,\n\n(AIII) [29] .\n\n. , . ,\n\n, , )\n\n(AIII) [5, 30] .\n\n(BIII) [30] .\n\n. , . .\n\n1.\n\nPCR , (AIII). (AIII). (Table 4) . \n\n2) \uba54\ub974\uc2a4 \ucf54\ub85c\ub098\ubc14\uc774\ub7ec\uc2a4 \uac10\uc5fc \ub178\ucd9c\uc790\uc758 \uc704\ud5d8\ub3c4 \ud3c9\uac00 \ubc0f \uad00\ub9ac , ,( , )\n\nHigh-risk close contact (\uace0\uc704\ud5d8 \ubc00\uc811\uc811\ucd09)\n\nHigh-risk close contact: contact under the aerosol-generating procedure (eg. nebulizer, intubation, endotracheal suction, bronchoscopy, etc.). Intermediate-risk close contact: contact within 2 m distance from the laboratory-confirmed MERS patient or stay at the same ward/floor of hospital exposed to laboratory-confirmed MERS patients. Casual contact: instant contact with >2 m distance from the laboratory-confirmed MERS patients (AIII) (Fig. 1 ).\n\n(AIII) ( Table 5 ).\n\n(AIII) ( \n\n3.\n\n,\n\n, ,\n\n. .\n\n, 32] . [11, 32] . [11, 31, 32] . [32, 33] . , ,\n\n. , [32] .\n\n, [11, 32] .\n\n, .\n\n, , [11, 31, 34, 35] .\n\n, , .\n\n, .\n\n, .\n\n(Powered Air Purifying Respirator, PAPR) .\n\n[32]. FFP2, KF94\n\n. , [11, 15, 31, 32, 34, 35] .\n\n( tting test) [32, 33] .\n\nPAPR .\n\n, .\n\n, [32, 33] .\n\n. . [11] . , [32, 33] . [11] . [5] [6] [7] .\n\n, , ,\n\n(AII) ( Table 7, 8) . , (Table 9 ). , ( ) (Fig. 2) .\n\n. . \n\n, .\n\n) ( Table 3 ) [28] , ( ).\n\n, , ,\n\n. , . \n\n. , , ,\n\n. \n\n. 99% (  12  30   1% ).\n\n. , (closed suction system) .\n\n(non-invasive positive-pressure ventilation with face mask)\n\n. , , ( \n\n, (Table 10) .\n\n, .\n\n, . (BII).\n\n(elective surgery) , (emergency surgery) (BIII).\n\n. , . [27] .\n\n(BII) [5] .\n\n(airborne precaution) (AIII) [29] .\n\n(laminar airflow)\n\n, (air duct) ,\n\n. ,\n\n. , (BIII) [36] .\n\n, .\n\n, . 99%\n\n( 12 30 ) [36] . . , (closed suction system) [36] .\n\n(BII) [29] . , . [17] .\n\n(CIII) [37] . , 19] .\n\n.\n\n\uba54\ub974\uc2a4 \uc758\ub8cc\uae30\uad00 \uac10\uc5fc\uad00\ub9ac\uc9c0\uce68 \u2022 \uae40\uc9c4\uc6a9 \uc678 (  12  30   1% ) [28] , (BII) [38] . , (AII) [36] .\n\n. 30 , [28] .\n\n1. , (AIII).\n\n(BII).\n\n3. 14 (AII).\n\n(BII).\n\n(AII).\n\n, (AIII). , . , [39, 40] .\n\n, , (AII) [41] .\n\n14 (AII) [3] . , 2 (BII) [42, 43] .\n\n. , , [43] . , (AII) [28] . , (BII) [16, 44] .\n\n1.\n\n, (AIII).\n\n3.\n\n(AIII).\n\n, (AIII).\n\n, , ,\n\n.\n\n(AIII). , ,\n\n.\n\n, .\n\n.\n\n\uae40\uc9c4\uc6a9 \uc678 \u2022 \uba54\ub974\uc2a4 \uc758\ub8cc\uae30\uad00 \uac10\uc5fc\uad00\ub9ac\uc9c0\uce68\n\n1.\n\n(BIII).\n\n(AII).\n\n, .\n\n(AII) [45] .\n\n, 12 , biosafety level 3 [45] .\n\n2) \ubd80\uac80\uc2e4\uc758 \ud658\uacbd\uad00\ub9ac (Table 11) . , ,\n\n(cut-proof synthetic mesh gloves) ] , (Fig. 4) . \n\n3.\n\n, (AIII).\n\n/ (AII) [11] .\n\n, .\n\n, ,\n\n(AIII).\n\n, , , , . \n\n. \n\n[ , \n\n1.\n\n, (AIII). "}